#1 Clinical Trials Search in Europe

Tamoxifen

Tamoxifen is a widely studied drug in clinical trials, primarily known for its use in breast cancer treatment. However, research is expanding to explore its potential in other conditions. This article summarizes key findings from various clinical trials investigating tamoxifen’s efficacy, safety, and applications in different medical scenarios.

Table of Contents

What is Tamoxifen?

Tamoxifen is a medication commonly used in the treatment of breast cancer. It belongs to a class of drugs known as selective estrogen receptor modulators (SERMs). Tamoxifen is also known by several other names, including Nolvadex, tamoxifen citrate, and ICI 46,474[1]. This drug has been widely used for over 30 years and has helped millions of women in their fight against breast cancer[2].

How Tamoxifen Works

Tamoxifen works by blocking the effects of estrogen in breast tissue. Estrogen can stimulate the growth of breast cancer cells in some types of breast cancer. By interfering with estrogen’s ability to bind to receptors on cancer cells, tamoxifen helps to slow down or stop the growth of these cancer cells[3].

This medication is particularly effective in treating what are known as hormone receptor-positive breast cancers. These are cancers whose cells have receptors for estrogen and/or progesterone on their surface[1].

Conditions Treated with Tamoxifen

While tamoxifen is primarily used to treat breast cancer, research is ongoing to explore its potential in treating other conditions. Here are the main conditions for which tamoxifen is used or being studied:

  • Breast Cancer: Tamoxifen is used to treat various stages of breast cancer, including early-stage, advanced, and metastatic (cancer that has spread to other parts of the body) breast cancer[4].
  • Breast Cancer Prevention: In some cases, tamoxifen may be prescribed to women at high risk of developing breast cancer as a preventive measure[3].
  • Neuroendocrine Tumors: Some studies are investigating the use of tamoxifen in treating certain types of neuroendocrine tumors, which are rare cancers that can occur in various parts of the body[5].
  • Chronic Hepatitis C: There is ongoing research to explore whether low doses of tamoxifen might be beneficial for patients with chronic hepatitis C who haven’t responded to standard treatments[6].

Dosage and Administration

Tamoxifen is typically taken orally (by mouth) in the form of tablets. The dosage can vary depending on the condition being treated and individual patient factors. Here are some common dosage regimens:

  • For breast cancer treatment, a common dose is 20 mg taken once daily[4].
  • In some studies, higher doses (such as 40 mg daily) are being explored[7].
  • Treatment duration can vary, but it’s often prescribed for 5 years or longer[3].

It’s crucial to take tamoxifen exactly as prescribed by your doctor. Do not change your dose or stop taking the medication without consulting your healthcare provider.

Effectiveness of Tamoxifen

Tamoxifen has proven to be highly effective in treating hormone receptor-positive breast cancer. Studies have shown that it can:

  • Reduce the risk of breast cancer recurrence by 39%[2].
  • Decrease mortality (death rate) by 30% in breast cancer patients[2].
  • Improve disease-free survival and overall survival in postmenopausal women with breast cancer[3].

The effectiveness of tamoxifen can vary depending on individual factors, including the specific type and stage of cancer, as well as genetic factors that influence how a person’s body processes the drug[8].

Potential Side Effects

Like all medications, tamoxifen can cause side effects. Common side effects may include:

  • Hot flashes
  • Nausea
  • Fatigue
  • Mood changes
  • Vaginal discharge or dryness

More serious but less common side effects can include an increased risk of blood clots and, rarely, uterine cancer. It’s important to discuss all potential side effects with your doctor[2].

Ongoing Research

Researchers continue to study tamoxifen to better understand its effects and explore new potential uses. Some areas of ongoing research include:

  • Optimizing dosage based on genetic factors[7].
  • Combining tamoxifen with other treatments to enhance its effectiveness[9].
  • Exploring its potential in treating other types of cancers and conditions[5][6].

As research continues, our understanding of tamoxifen and its potential uses may expand, potentially offering new treatment options for patients with various conditions.

Aspect Details
Primary Use Treatment of ER-positive breast cancer
Other Potential Uses Oesophageal cancer, neuroendocrine tumors, bladder cancer, managing IUD-related bleeding
Common Dosages 20-80mg daily, orally
Treatment Duration Varies from weeks to years depending on study design
Key Outcomes Measured Tumor response, progression-free survival, changes in biomarkers (e.g., Ki67)
Common Side Effects Hot flashes, vaginal discharge, menstrual changes
Combination Therapies Often studied in combination with other drugs or as part of multimodal treatment approaches

FAQ

  • What is the primary use of tamoxifen in clinical trials? Tamoxifen is primarily used in clinical trials for the treatment of breast cancer, especially in patients with estrogen receptor (ER)-positive breast cancer. It acts as an anti-estrogen medication to block the effects of estrogen on tumor cells.
  • Are there any studies exploring tamoxifen's use beyond breast cancer? Yes, clinical trials are investigating tamoxifen's potential in other conditions. For example, there are studies on its use in oesophageal cancer, neuroendocrine tumors, bladder cancer, and even in managing bleeding associated with intrauterine devices.
  • How is tamoxifen typically administered in clinical trials? In most clinical trials, tamoxifen is administered orally. The dosage varies depending on the study, but common doses range from 20mg to 80mg daily. Some trials use it as a single agent, while others combine it with other treatments.
  • What are some common side effects of tamoxifen observed in clinical trials? While specific side effects can vary between studies, common side effects of tamoxifen may include hot flashes, vaginal discharge, and changes in menstrual cycles. More serious but less common side effects can include blood clots and increased risk of endometrial cancer.
  • How long do patients typically take tamoxifen in clinical trials? The duration of tamoxifen treatment in clinical trials varies widely depending on the study design and objectives. It can range from a few weeks in short-term studies to several years in long-term breast cancer prevention or treatment trials.

Ongoing Clinical Trials on Tamoxifen

  • Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of tamoxifen loading dose and Ki67 response in breast cancer patients before surgery (ENDO-67)

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Safety and Tolerability of Tamoxifen in Cystic Fibrosis Patients Not Eligible for CFTR Modulator Therapy

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Long-term safety study of ribociclib with letrozole, tamoxifen, or goserelin acetate in patients with HR-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Greece Italy Poland Portugal Spain

  • Study on the Effects of Chemotherapy and Endocrine Therapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer Using Tamoxifen and Anastrozole

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Ireland

  • Evaluation of Abemaciclib with Standard Endocrine Therapy in Patients with High Risk, Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Hungary Italy Poland +2

  • Study on Giredestrant or Tamoxifen for Premenopausal Women with Early ER-Positive, HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • Estrogen Receptor (ER): A protein found on cells that binds to estrogen. Some cancer cells, particularly in breast cancer, have these receptors and depend on estrogen for growth.
  • HER2-negative: Refers to breast cancer cells that do not have a high amount of a protein called HER2 on their surface. This affects the treatment approach.
  • Ki67: A protein in cells that increases as they prepare to divide into new cells. A high level of Ki67 means that the cancer cells are dividing and the cancer is growing quickly.
  • Neoadjuvant Therapy: Treatment given before the main treatment, usually before surgery. It's often used to shrink a tumor.
  • Pathological Complete Response (pCR): The absence of all detectable cancer after treatment, as determined by pathologic examination of tissue.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • RECIST Criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Selective Estrogen Receptor Modulator (SERM): A class of drugs that act on the estrogen receptor. Tamoxifen is a type of SERM.

References

  1. https://clinicaltrials.gov/study/NCT00066690
  2. https://clinicaltrials.gov/study/NCT00849030
  3. https://clinicaltrials.gov/study/NCT00002646
  4. https://clinicaltrials.gov/study/NCT00002777
  5. https://clinicaltrials.gov/study/NCT03870399
  6. https://clinicaltrials.gov/study/NCT00749138
  7. https://clinicaltrials.gov/study/NCT04961632
  8. https://clinicaltrials.gov/study/NCT01124695
  9. https://clinicaltrials.gov/study/NCT02322853